Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 47 (TRAJ47)
- Target
- TRAJ47
- Molecular classification
- Other (immunogenetic segment), T cell receptor gene segment, Not a receptor, enzyme, transporter, transcription factor, etc.
01
Overview
TRAJ47 refers to the 47th Joining (J) gene segment in the T cell receptor alpha (TRA) locus, located on human chromosome 14. This segment does not encode an independently expressed protein or receptor but provides one of many variable sequences incorporated during somatic recombination of the TCR alpha chain in developing T cells. The presence of multiple TRAJ segments allows for the massive diversity required for the adaptive immune response, where each T cell expresses a unique receptor tailored for antigen recognition. TRAJ47 is not a classical "target" in pharmacology or biotechnology and is not associated directly with any therapeutic interventions, disease biomarkers, or drug mechanisms. It is best understood as an immunogenetic building block in T cell receptor formation. Key clarification: TRAJ47 is not the same as a protein, functional receptor, or therapeutic target—it is a DNA gene segment within the TCR alpha locus, critical for immune diversity but not a direct pharmacological entity.
- Other names
- T cell receptor alpha joining 47TRAJ47
02
Mechanism of action
None. TRAJ47 is not a functional molecule or target for drug action, but serves as a V(J) gene segment for TCR alpha chain diversity
03
Biological functions
Diversity generation in the adaptive immune system through V(J) recombination for the T cell receptor alpha chainFacilitates production of highly variable T cell receptors for antigen recognitionDoes not have direct functions such as signal transduction, proliferation, or apoptosis, but enables antigen recognition diversity
04
Disease associations
Indirect roles in: Immunity, infection responseAbnormal recombination in TRAJ segments can theoretically alter TCR diversity and affect susceptibility to autoimmune disease, infection, or immune deficiencies, but TRAJ47 itself is not directly implicated as a disease gene or biomarker
05
Safety considerations
None. As a genomic segment facilitating recombination, TRAJ47 itself has no notable safety issues or therapeutic challenges
06
Interacting drugs
None. No drugs are known to interact directly or specifically with TRAJ47
07
Biomarkers
None. TRAJ47 is not used as a clinical biomarker for patient selection or efficacy monitoring
Beyond the preview
Go deeper on T cell receptor alpha joining 47 (TRAJ47).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell receptor alpha joining 47 (TRAJ47).